Markets:

Overview

News

Currencies

International

Treasuries

Kazia Therapeutics Limited - American Depositary Shares (NQ:KZIA)

12.09 -0.17 (-1.39%)

Streaming Delayed Price Updated: 12:22 PM EDT, Apr 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kazia Therapeutics Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >

Kazia Therapeutics' Shares Gain Following FDA Orphan Drug Status For Childhood Brain Cancer Drug ↗

June 17, 2022

The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kazia Therapeutics’ (NASDAQ: KZIA) Paxalisib for the treatment of atypical rhabdoid / teratoid tumors...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 17, 2022

Via Benzinga

Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer

May 26, 2022

LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address...

From Edison Investment Research Limited

Via AccessWire

Kazia Therapeutics Concludes Mid-Stage Paxalisib Study In Brain Cancer ↗

April 21, 2022

Kazia Therapeutics Limited (NASDAQ: KZIA) has completed a Phase 2 study of paxalisib in glioblastoma.

Via Benzinga

The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data ↗

April 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts

March 30, 2022

LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential...

From Edison Investment Research Limited

Via AccessWire

A Peek Into The Markets: US Stock Futures Gain After S&P 500 Hits Record High ↗

December 13, 2021

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged more than 200 points in the previous session. Investors are awaiting earnings...

Via Benzinga

Topics Stocks

60 Biggest Movers From Yesterday ↗

December 07, 2021

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore...

Via Benzinga

Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients ↗

December 03, 2021

Australia-based Kazia Therapeutics Limited (NASDAQ: KZIA) announced final data from a Phase 2 study of paxalisib as first-line therapy in patients with...

Via Benzinga

A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings ↗

November 15, 2021

Pre-open movers U.S. stock futures traded higher in early pre-market trade after closing higher in the prior session. Investors are awaiting earnings results from Tyson Foods,...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 ↗

October 14, 2021

Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:

Via Benzinga

Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4

October 14, 2021

LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly...

From Edison Investment Research Limited

Via AccessWire

Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis

April 20, 2021

LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for...

From Edison Investment Research Limited

Via AccessWire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 14, 2021

Gainers Akumin (NASDAQ:AKU) shares increased by 13.54% to $3.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $247.0...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.